Researchers Urge More Company-To-Company Collaboration On Clinical Trials
This article was originally published in The Gray Sheet
Executive Summary
With cost and time commitments ballooning for device and drug clinical development, some prominent researchers are pressing for companies with similar products to join together on new FDA pivotal trials rather than go it alone.
You may also be interested in...
Medtronic’s RAFT Keeps Hopes Afloat For Shift To CRT In Milder Heart Failure
Data reported last week could hasten moves by electrophysiologists to implant price-premium cardiac resynchronization therapy systems rather than conventional defibrillators in patients with earlier stage heart failure.
FDA Contributes Funds To Industry Post-Stenting Antiplatelet Trial
FDA is contributing $1.5 million to a large, collaborative clinical study designed to find out the optimum length of time to give anti-clotting drugs to patients with coronary drug-eluting stents
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.